Pediatric obesity drug development sits at the intersection of evolving clinical standards and statutory obligations under the Pediatric Research Equity Act. Sponsors planning an anti-obesity program need to know which populations FDA has accepted, what trial designs and BMI-based endpoints supported adolescent labeling, and how pediatric study requirements were waived, deferred, or fulfilled across precedent products.
The analysis below reviews each drug whose current FDA labeling covers pediatric weight management. For each product it sets out the pediatric approval action, the design and primary endpoint of the pivotal pediatric trial, and the regulatory path to the pediatric indication, including PREA waivers and deferrals, Written Request exclusivity, and orphan-designation exemptions. Each finding is cited to FDA labeling and review documents.
FDA-approved drugs for pediatric and adolescent obesity: clinical evidence and PREA requirements
FDA has approved five drugs whose current labeling establishes safety and effectiveness for weight management in pediatric patients. Four cover general (polygenic) obesity in adolescents aged 12 years and older: orlistat (Xenical), liraglutide (Saxenda), phentermine/topiramate extended-release (Qsymia) and semaglutide injection (Wegovy). The fifth, setmelanotide (Imcivree), is limited to rare genetic obesity (BBS or POMC, PCSK1 or LEPR deficiency, labeled from age 2) and acquired hypothalamic obesity (labeled from age 4). Each adolescent approval rested on one randomized, double-blind, placebo-controlled trial of roughly one year, with a BMI-based primary endpoint. The PREA history differs by product. For Saxenda, Qsymia and Wegovy, FDA waived the youngest age groups and deferred the older pediatric groups at adult approval. The later adolescent efficacy supplement then fulfilled the 12 to 17 year requirement. Xenical's adolescent data came from a pediatric Written Request linked to exclusivity. Imcivree was largely exempt from PREA because of orphan designation.
Summary of pediatric approvals
| Product (application) | Pediatric population in current labeling | Pediatric approval action | Pivotal pediatric trial | Primary endpoint result |
|---|---|---|---|---|
| Xenical (orlistat), NDA 020766 | 12 years and older with obesity 134 | Efficacy supplement S-018, December 12, 2003 (adolescents 12 to 16) 481477 | 54 weeks, n=539, ages 12 to 16 135 | BMI −0.55 kg/m² vs +0.31 kg/m² placebo (p=0.001) 136 |
| Saxenda (liraglutide), NDA 206321 | 12 years and older, body weight above 60 kg, BMI corresponding to adult 30 kg/m² by Cole criteria 9798 | December 4, 2020 82 | 56 weeks, n=251, ages 12 to 17 560 | BMI SDS treatment difference −0.22 (95% CI −0.37 to −0.08) 561 |
| Qsymia (phentermine/topiramate ER), NDA 022580 | 12 years and older, BMI at or above the 95th percentile for age and sex 299300 | S-021, June 24, 2022 298255 | 56 weeks, n=223, ages 12 to 17 302 | BMI −4.8% (7.5/46 mg) and −7.1% (15/92 mg) vs +3.3% placebo 536 |
| Wegovy (semaglutide injection), NDA 215256 | 12 years and older with obesity 201 | S-005, December 23, 2022 308327 | 68 weeks, n=201 395 | BMI −16.1% vs +0.6% placebo 398 |
| Imcivree (setmelanotide), NDA 213793 | 2 years and older with BBS or POMC, PCSK1 or LEPR deficiency; 4 years and older with acquired hypothalamic obesity 177 | Original November 25, 2020 (6 years and older) and supplements in 2022, 2024 and 2026 414417422424 | Small single-arm and randomized trials in mixed adult and pediatric populations 415179 | See product section |
Adolescent obesity approvals
Xenical (orlistat)
Xenical was the first of these products to gain adolescent labeling. FDA approved efficacy supplement S-018 on December 12, 2003. The supplement revised labeling for obesity management in adolescents aged 12 to 16 481477. It responded to an FDA pediatric Written Request and sought a pediatric exclusivity determination 482. The medical team leader memo states that Roche ran the two requested pediatric studies as the Written Request specified. A later clinical review describes the adolescent study as the basis for six months of exclusivity 483484.
Clinical evidence. The pivotal study was a 54-week, multicenter, double-blind, placebo-controlled trial in 539 adolescents aged 12 to 16. Of these, 357 received orlistat 120 mg three times daily and 182 received placebo. Obesity was defined as a baseline BMI 2 units above the US weighted mean for the 95th percentile for age and sex 134135. BMI was the primary efficacy parameter. After one year, mean BMI fell by 0.55 kg/m² with Xenical and rose by 0.31 kg/m² with placebo (p=0.001) 136. Adolescent adverse effects were generally similar to those seen in adults, chiefly fatty or oily stool, oily spotting and oily evacuation. The label recommends a daily multivitamin containing fat-soluble vitamins 485. The current label states that pediatric safety and effectiveness are established at 12 years and older 134.
Pediatric requirements. The 1999 original approval letter deferred pediatric studies until December 2, 2000 and asked for a pediatric development plan 77. Recent supplements (2015, 2016, 2022 and 2026) were exempt from PREA because none of the triggering criteria applied 73747576.
Saxenda (liraglutide 3 mg)
PREA at adult approval. The December 23, 2014 Saxenda approval letter waived pediatric studies for ages 0 to 6, inclusive, because the studies were impossible or highly impracticable. FDA explained that weight maintenance, not weight loss, is the goal for obese children aged 2 to 6. Weight loss is not recommended below age 2 because of growth and neurodevelopmental needs. FDA deferred studies for ages 7 to 17 because the product was ready for adult approval 276. The PMR development templates describe PK/PD studies in patients aged 12 to 17 and 7 to 11 282283.
Fulfillment. The December 4, 2020 supplement letter identifies PREA PMR 2802-03 as a 56-week randomized, double-blind, placebo-controlled study in patients aged 12 to 17. It states that S-012 contained the final report and that the requirement was fulfilled. Other PMRs from the 2014 letter remained open 277278279280281.
Clinical evidence. The adolescent trial enrolled 251 pubertal patients aged 12 to 17 and began with a 12-week lifestyle run-in. Patients then received once-daily Saxenda or placebo for 56 weeks 560. The primary endpoint was change in BMI standard deviation score (BMI SDS). At week 56, BMI SDS changed by −0.23 with Saxenda and −0.00 with placebo, an estimated treatment difference of −0.22 (95% CI −0.37 to −0.08; p=0.0022) 561. Adverse reactions led 10.4% of Saxenda patients to discontinue, compared with none on placebo 562. One Saxenda-treated pediatric patient (0.8%) developed pancreatitis 563.
Indication specifics. Saxenda's pediatric indication requires body weight above 60 kg and an initial BMI corresponding to 30 kg/m² or greater for adults under international (Cole) cut-offs. It does not use a US percentile threshold 9798. The current label states that safety and effectiveness have not been established below age 12 442443.
Qsymia (phentermine and topiramate extended-release)
PREA at adult approval. The July 17, 2012 original approval letter waived studies for ages 0 to 6. FDA cited evidence that Qsymia would be ineffective and unsafe in this group, along with concerns about topiramate's pediatric safety and possible effects of both components on growth, development, learning, memory and behavior 219237. Studies for ages 7 to 17 were deferred 238. The PMR development templates set out four PREA studies 239243247251:
| Deferred PREA study | Final protocol | Study completion | Final report |
|---|---|---|---|
| PK/PD dose-finding study, ages 12 to 17 239 | June 30, 2015 240 | November 30, 2015 241 | May 31, 2016 242 |
| 52-week randomized, double-blind, placebo-controlled safety and efficacy study, ages 12 to 17 243 | November 30, 2016 244 | March 31, 2018 245 | September 30, 2018 246 |
| PK/PD dose-finding study, ages 7 to 11 247 | March 30, 2019 248 | June 30, 2019 249 | December 31, 2019 250 |
| 52-week randomized, double-blind, placebo-controlled safety and efficacy study, ages 7 to 11 251 | June 30, 2019 252 | October 31, 2021 253 | April 30, 2022 254 |
Fulfillment. The June 24, 2022 S-021 letter states that the pediatric study requirement for ages 12 to 17 has been fulfilled 255.
Clinical evidence. Study 3 was a 56-week randomized, double-blind, placebo-controlled trial in 223 patients aged 12 to 17 with BMI at or above the 95th percentile. Patients received placebo (n=56), Qsymia 7.5 mg/46 mg (n=54) or Qsymia 15 mg/92 mg (n=113), alongside lifestyle modification 302. The primary efficacy parameter was mean percent change in BMI at week 56 535.
| Week 56 outcome (ITT-washout, primary) | Placebo | 7.5 mg/46 mg | 15 mg/92 mg |
|---|---|---|---|
| LS mean BMI change | +3.3% | −4.8% | −7.1% |
| Difference from placebo | n/a | −8.1 points | −10.4 points |
| At least 5% BMI reduction | 13.6% | 44.0% | 52.2% |
| At least 10% BMI reduction | 4.5% | 33.5% | 44.4% |
Source: 536537538539. Thirty-eight percent of randomized patients withdrew before week 56. Missing data were imputed with a placebo-based washout method 540541.
Pediatric safety. Height velocity was 1.3 to 1.4 cm/year lower with Qsymia than with placebo 583. Mood-related reactions and sleep disorders were more frequent with Qsymia. Depression occurred in 0%, 2% and 4% of the placebo, low-dose and high-dose groups 584585. A heart rate increase of more than 10 bpm at a single time point occurred in 46.4%, 55.6% and 64.6% of the respective groups 592.
Wegovy (semaglutide 2.4 mg injection)
PREA at adult approval. The June 4, 2021 original approval letter waived pediatric studies under age 6. FDA found no meaningful therapeutic benefit over existing therapies and did not expect use in a substantial number of these patients 319325. The review records an agreed deferral for ages 6 to under 18 326.
Fulfillment and indication. FDA approved efficacy supplement S-005 on December 23, 2022. The letter states that the pediatric study requirement for ages 12 to under 18 was fulfilled. A PREA PMR from the 2021 letter remained open 308327. The resulting indication covered pediatric patients aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex 202203. The November 27, 2024 S-015 supplement added 1.7 mg once weekly as an additional maintenance dose for patients aged 12 to under 18 461. That letter marked PMR 4472-1, exposure and exposure-response analyses supporting the 1.7 mg pediatric dose, as fulfilled 463. It also restated that the 12 to 17 requirement was fulfilled 331.
Clinical evidence. The pediatric trial (Study 7, NCT04102189) was a 68-week, double-blind, randomized, placebo-controlled, multicenter trial 462. It enrolled 201 pubertal patients aged 12 and older with BMI at or above the 95th percentile. After a 12-week lifestyle run-in, patients were randomized 2:1. A 16-week escalation to 2.4 mg (or the maximum tolerated dose) was followed by 52 weeks of maintenance. The primary endpoint was percent change in BMI to week 68 395396.
| Week 68 outcome | Wegovy (n=134) | Placebo (n=67) | Difference |
|---|---|---|---|
| BMI change | −16.1% | +0.6% | −16.7 points (95% CI −20.3 to −13.2) 398 |
| Body weight change | −14.7% | +2.7% | −17.4 points 399 |
| At least 5% BMI reduction | 77.1% | 19.7% | 57.4 points 400 |
Source: 397.
Pediatric safety. Compared with Wegovy-treated adults, pediatric patients had higher incidences of cholelithiasis, cholecystitis, hypotension, rash and urticaria 624. Cholelithiasis occurred in 3.8% of pediatric Wegovy patients and 0% of pediatric placebo patients, versus 1.6% of Wegovy-treated adults 625626. Nausea (42% vs 18%) and vomiting (36% vs 10%) were the most common pediatric adverse reactions 627.
Ongoing PREA obligations. A July 21, 2023 supplement letter again waived pediatric studies under age 6 and deferred studies for ages 6 to 18 328. For the MASH indication (S-024, August 15, 2025), FDA waived studies under age 6 and deferred studies for ages 6 to under 17. PMR 4882-2 requires a randomized, placebo-controlled trial in patients aged 6 to under 17 with non-cirrhotic MASLD with fibrosis, with a final report due January 2030 332333334335. The oral Wegovy tablet (NDA 218316, approved December 22, 2025) has no pediatric indication 209151. Its review anticipates a PREA PMR for population PK and exposure-response analyses in patients aged 12 to under 18 214.
Rare genetic and hypothalamic obesity: Imcivree (setmelanotide)
Imcivree is indicated to reduce excess body weight and maintain weight reduction in adults and pediatric patients with specific causes of obesity. These are acquired hypothalamic obesity (age 4 and older) and Bardet-Biedl syndrome (BBS) or POMC, PCSK1 or LEPR deficiency (age 2 and older). It is not indicated for general (polygenic) obesity 177.
Approval sequence.
- November 25, 2020: original approval for POMC/PCSK1 and LEPR deficiency in patients aged 6 and older. After one year, 8 of 10 POMC/PCSK1 patients (80%) and 5 of 11 LEPR patients (45.5%) achieved at least 10% weight loss. These results pool adults and children; 38% of the efficacy population was aged 16 or younger 414415416.
- June 16, 2022: BBS added for patients aged 6 and older, based on a 66-week study with a 14-week randomized, placebo-controlled period followed by 52 weeks of open-label treatment. The study included 22 participants aged 6 to 17 417418419.
- December 20, 2024: extension to ages 2 to under 6, based on a 52-week open-label trial in 12 children (3 POMC, 4 LEPR, 5 BBS) 422423.
- March 19, 2026: acquired hypothalamic obesity added for patients aged 4 and older 424425. Trial 1 randomized 142 patients aged 4 and older (94 Imcivree, 48 placebo); 31% were aged 12 to under 18 and 23% were aged 4 to under 12 179180181. At week 52, BMI fell by 15.84% with Imcivree and rose by 2.55% with placebo. The placebo-adjusted difference was −18.40 points (95% CI −21.94 to −14.85), in the combined adult and pediatric population 182183.
PREA status. The original application was exempt from PREA because setmelanotide held orphan designation for POMC (including PCSK1) and LEPR deficiency 108. The 2022 BBS supplement was likewise exempt on orphan grounds 109. The December 2024 supplement was exempt because no PREA trigger applied 110. For the 2026 hypothalamic obesity supplement, FDA waived studies from birth to under 4 years as impossible or highly impracticable 111.
Products without a pediatric obesity indication
Zepbound (tirzepatide). Current labeling states that safety and effectiveness have not been established in pediatric patients 504507. At the November 8, 2023 weight-management approval, FDA waived studies for ages 0 to 5. It found no meaningful therapeutic benefit and did not expect substantial use in that group 363367. FDA agreed to defer studies for ages 6 to under 18 366. The deferred program includes a 72-week safety and efficacy trial in adolescents aged 12 to 17, with study completion due February 2027 and a final report due August 2027 368369370. It also includes a PK/PD dose-selection study in children aged 6 to 11 371372. The obstructive sleep apnea supplement (December 20, 2024) added PMR 4759-1, a 72-week study in adolescents with obesity-related OSA, with a draft protocol due June 2031 374375376.
Adipex-P (phentermine). The label states that pediatric safety and effectiveness have not been established. It does not recommend use for pediatric obesity, which requires long-term treatment, because Adipex-P is approved only for short-term therapy 344. The label also states that Adipex-P is not recommended for patients aged 16 or younger 345.
The PREA pattern and current FDA expectations
Saxenda, Qsymia and Wegovy show a consistent template. At adult approval, FDA waived the youngest children, citing ages 0 to 6 or under 6. The waiver rationale was either that weight loss is not the treatment goal in that group or that the product offers no meaningful benefit there 276237325. FDA deferred older pediatric groups to postmarketing requirements 276238326. A later adolescent efficacy supplement then fulfilled the 12 to 17 requirement 277255327. The requirements for the 6 or 7 to 11 year cohort remain the open part of these programs. None of the current labels for these products establishes use below age 12 442134.
FDA's January 7, 2025 draft guidance, Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction, sets out these expectations 606:
- Include children aged 6 and older, generally in separate trials or cohorts for adolescents (12 and older) and children (6 to 11) 607.
- Generally enroll patients with BMI at or above the 95th percentile, or at or above the 85th percentile with a weight-related comorbidity in adolescents, after documented insufficient response to lifestyle modification 608.
- Use a BMI-based primary endpoint, such as mean percent change in BMI, because children are still growing 609.
- Run randomized, double-blind, placebo-controlled phase 3 trials of at least one year at the target dose 610.
- Submit the initial pediatric study plan no later than 60 days after the end-of-phase 2 meeting. Adult efficacy and safety data should generally be available before pediatric studies of a new drug begin 611.
- Meet PREA obligations with age-appropriate formulations unless a waiver, deferral or exception applies 612.
The adolescent trials behind the approved products used different primary endpoints: absolute BMI change for Xenical, BMI SDS for Saxenda, and percent BMI change for Qsymia and Wegovy 136561535396. Because of this variation, labeled effect sizes cannot be compared directly across products. The draft guidance's preference for percent change in BMI is likely to make future pediatric programs more comparable.